News Sentiment

LAB sentiment intelligence

Standard Biotools Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.92 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

71/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.6% over one week, +3.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to book forward of Standard BioTools Inc. – NASDAQ:LAB

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 71/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend inactive 3.5% over four weeks
Fair value -46.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 41
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 12
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 11
TradingView 6
GlobeNewswire 3
Minichart 2
StockStory 2
simplywall.st 2
Investing.com Australia 1

Event Lens

What the news is about

Classified themes
Earnings 18
Market update 17
Deals and strategy 15
Balance sheet 2
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
TradingView Direct company coverage

Price to book forward of Standard BioTools Inc. – NASDAQ:LAB

This article provides the "Price to book forward" value for Standard BioTools Inc. (NASDAQ: LAB). It indicates that the market was closed at the time of publication, with no trades observed. The data presented is provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Standard BioTools Inc. – BOATS:LAB

The article focuses on the "Price to earnings forward" metric for Standard BioTools Inc. (LAB), as available through the Blue Ocean Alternative Trade System (BOATS:LAB) on TradingView. It appears to list financial data points for this specific metric over various periods, showing

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Standard BioTools Inc. – NASDAQ:LAB

This article provides financial data for Standard BioTools Inc. (NASDAQ: LAB), specifically its enterprise value to revenue forward. It appears to be a data point or a financial metric provided by TradingView, indicating a key valuation ratio for the company over a future period.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Standard BioTools Inc. – NASDAQ:LAB

This article presents the enterprise value to EBITDA forward of Standard BioTools Inc. (NASDAQ:LAB). The information is provided by TradingView, a platform offering financial market data and tools. The article is a snapshot of financial data without further analysis.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 01:11
Source
TradingView
Stock Titan Direct company coverage

Standard BioTools (LAB) director receives new RSU and stock option awards

Standard BioTools (LAB) director Carey Thomas D. received equity compensation comprising 99,116 restricted stock units (RSUs) and stock options for 263,884 shares. The RSUs vest by June 18, 2027, or prior to the next annual stockholders' meeting, while the stock options, with an

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 12:11
Source
Stock Titan
Stock Titan Direct company coverage

Standard BioTools (LAB) awards 500,000 RSUs to chief business officer

Standard BioTools (LAB) has granted 500,000 Restricted Stock Units (RSUs) to its SVP & Chief Business Officer, Sean Mackay. These RSUs, which were provided at no cash cost, will vest in two tranches—40% on June 20, 2027, and 60% on June 20, 2028—contingent on Mackay's continued s

Tone
Neutral 50/100
Event
Balance sheet
Published
24 Jun 2026 11:41
Source
Stock Titan
Investing.com Australia Direct company coverage

Form 4 Standard Biotools Inc For: 23 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Standard Biotools Inc. The report, dated for June 23, 2026, was published on June 24, 2026, at 07:52 am, and is accompanied by current market data. The content is brief and serves primarily as an announcement of the f

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 07:52
Source
Investing.com Australia
Stock Titan Direct company coverage

Eli Casdin (LAB) granted RSUs and stock options, reports large fund holdings

STANDARD BIOTOOLS director and 10% owner Eli Casdin reported receiving new equity awards, including 99,116 Restricted Stock Units and stock options for 175,923 shares. These awards are part of his compensation and vest over time, contingent on continued service. The filing also d

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 00:39
Source
Stock Titan
Stock Titan Direct company coverage

STANDARD BIOTOOLS (NASDAQ: LAB) director receives new RSU and stock option awards

STANDARD BIOTOOLS (NASDAQ: LAB) director Troy Cox received new RSU and stock option awards as part of his compensation. He was granted 99,116 RSUs vesting by June 18, 2027, and stock options for 175,923 shares with an exercise price of $0.8297, vesting in monthly installments sta

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

STANDARD BIOTOOLS (LAB) director Frank Witney receives new RSU and stock option awards

STANDARD BIOTOOLS INC. director Frank Witney reported receiving new equity awards, consisting of 99,116 Restricted Stock Units (RSUs) and a stock option for 175,923 shares with an exercise price of $0.8297. These awards increase his stake in the company and are subject to vesting

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Jun 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

STANDARD BIOTOOLS (NASDAQ: LAB) director awarded RSUs and stock options in new Form 4

STANDARD BIOTOOLS director Eloi Fenel M was granted 99,116 Restricted Stock Units (RSUs) and stock options for 175,923 shares with an exercise price of $0.8297 per share. The RSUs vest by June 18, 2027, or before the next annual stockholders’ meeting, and the options vest in mont

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 21:10
Source
Stock Titan
The Malone Telegram Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)

Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of AstroNova, Inc. (ALOT), Open Lending Corporation (LPRO), Huntsman Corporation (HUN), and Standard BioTools Inc. (LAB) regarding their respective acquisition agreements. The inves

Tone
Negative 38/100
Event
Deals and strategy
Published
19 Jun 2026 16:39
Source
The Malone Telegram
Stock Titan Direct company coverage

Standard BioTools (LAB) investors approve 2026 equity plan and ESPP share increase

Standard BioTools Inc. stockholders approved a new 2026 Equity Incentive Plan and an amendment to the 2017 Employee Stock Purchase Plan, increasing reserved shares by 1,200,000. Additionally, shareholders elected three Class I directors, gave advisory approval for 2025 executive

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 20:30
Source
Stock Titan
TradingKey Direct company coverage

Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Standard BioTools Inc (LAB). It notes that no dividend data is available for the past five years and no historical stock split data is provided. The article also includes current stock information for LAB, su

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:09
Source
TradingKey
Business Wire Direct company coverage

LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. The investigation focuses on whether Standard BioTools' board failed to secure the best possible price and conduct a fair sales proces

Tone
Negative 30/100
Event
Deals and strategy
Published
15 Jun 2026 14:40
Source
Business Wire
Stock Titan Direct company coverage

[SCHEDULE 13D/A] STANDARD BIOTOOLS INC. Amended Major Shareholder Report

This SCHEDULE 13D/A filing reports an amended major shareholder report for Standard BioTools Inc. (LAB) by Casdin Capital, LLC and affiliated entities. The filing details their beneficial ownership percentages and outlines a recent merger agreement between Standard BioTools Inc.

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jun 2026 21:39
Source
Stock Titan
BioPharma Dive Direct company coverage

Stealthy startup Treeline plans a reverse merger

Stealthy biotechnology firm Treeline Biosciences, led by former Loxo Oncology CEO Josh Bilenker, is set to go public via a reverse merger with microfluidics company Standard BioTools. Treeline will retain 84.5% ownership of the combined entity, bringing nearly $900 million in cas

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jun 2026 14:10
Source
BioPharma Dive
Fenwick & West LLP Direct company coverage

Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools

Fenwick is representing Treeline Biosciences in its definitive merger agreement with Standard BioTools Inc. The combined company will operate as Treeline Biosciences, focusing on advancing its pipeline of small molecule inhibitors, protein degraders, and antibody-drug conjugates.

Tone
Positive 76/100
Event
Deals and strategy
Published
08 Jun 2026 17:10
Source
Fenwick & West LLP
GlobeNewswire Direct company coverage

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools and Treeline Biosciences have announced a definitive merger agreement in an all-stock transaction, with the combined company set to operate as Treeline Biosciences. The merger is expected to close in the second half of 2026, creating a well-capitalized entity wi

Tone
Positive 66/100
Event
Deals and strategy
Published
08 Jun 2026 16:09
Source
GlobeNewswire
Minichart Direct company coverage

Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12

Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. have announced an all-stock merger to form a new public biopharma company, Treeline Biosciences (TRLN), focused on oncology and precision medicines. The combined entity is expected to have over $900 million in pr

Tone
Positive 67/100
Event
Deals and strategy
Published
08 Jun 2026 15:08
Source
Minichart
citybiz Direct company coverage

Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company

Standard BioTools Inc. (NASDAQ: LAB) is merging with Treeline Biosciences in an all-stock transaction, transforming Standard BioTools into a clinical-stage biotechnology company focused on precision medicines for cancer and other serious diseases. The combined entity, which will

Tone
Positive 71/100
Event
Deals and strategy
Published
08 Jun 2026 12:08
Source
citybiz
TradingView Direct company coverage

Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion

Standard BioTools (LAB) has agreed to an all-stock merger with Treeline Biosciences, valuing Treeline at $2.5 billion and Standard BioTools at $460 million, adjusted for net cash. Post-merger, former Treeline holders will own approximately 84% of the combined entity, which will b

Tone
Positive 70/100
Event
Deals and strategy
Published
08 Jun 2026 12:08
Source
TradingView
Fierce Biotech Direct company coverage

Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger

Treeline Biosciences, a well-funded cancer company, plans to go public by merging with omics outfit Standard BioTools, with the combined entity retaining the Treeline name and Nasdaq ticker TRLN. The deal, expected to close in the second half of 2026, aims to leave Treeline with

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jun 2026 10:37
Source
Fierce Biotech
Moomoo Direct company coverage

Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Standard BioTools, Inc. (NASDAQ: LAB) has announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received a letter from Nasdaq confirming its closing bid price was at $1.00 per share or greater for ten consecutive business days, resolving th

Tone
Positive 70/100
Event
Market update
Published
08 Jun 2026 10:08
Source
Moomoo